Study of Efgartigimod for teens with chronic ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an IV medicine called efgartigimod for teenagers (ages 12 to under 18) who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if it can safely help raise platelet counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 18 years old (but not yet 18).
- You have had primary ITP (not caused by another condition) for more than 12 months.
- You have tried at least one ITP treatment before, such as steroids, IVIg, anti-D immunoglobulin, TPO receptor agonists, or rituximab.
- You had a good response (platelet count of 50 or higher) to at least one of these treatments: prednisone, other steroids, IVIg, or anti-D immunoglobulin.
- Your platelet count has been low (less than 30) on average, and you did not respond well enough to a prior ITP treatment.
- You do not have another cause for low platelets (such as hereditary conditions or bleeding emergencies).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a “dose-dense” rituximab schedule can help children and teens with newly diagnosed, high-risk immune thrombocytopenia (ITP). It aims to raise/maintain platelet counts and control bleeding, while carefully checking safety.
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
This trial tests whether adding iguratimod (a medicine that helps control immune system activity) to a low dose of rituximab (a targeted therapy for immune cells) works better than low-dose rituximab alone for people with ITP that has not responded to steroid treatment or that comes back after steroids are stopped.
This trial tests a new drug called ESG206 for adults with immune thrombocytopenia (ITP) whose platelet counts remain very low despite previous treatments like steroids or IVIG. The goal is to see if ESG206 can safely help raise platelet levels and reduce bleeding risk.
This study tests an investigational drug called efgartigimod, given through a vein, for adults with chronic immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it safely raises platelet counts and reduces bleeding risk.
This study tests a drug called efgartigimod to see if it can prevent relapses in people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who are currently in remission. It may help by reducing the immune activity that causes the condition.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.